首页 | 本学科首页   官方微博 | 高级检索  
     


Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Affiliation:1. Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;2. Faculty of Medicine, Kobe University, Kobe, Japan;3. Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan;4. Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt;5. Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan;6. Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan;7. One Health Research Center, Hokkaido University, Sapporo, Japan;8. Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;9. Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan;10. Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan;11. Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel;12. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;13. Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan;14. Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan;15. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan;16. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;17. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;18. Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan;19. Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan;20. International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan;21. Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan;22. Tokyo Metropolitan Institute of Public Health, Tokyo, Japan;23. Interpark Kuramochi Clinic, Utsunomiya, Japan;24. Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan;25. Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan;26. Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan;27. Center for Animal Disease Control, University of Miyazaki, Chiba, Japan;28. Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan;29. Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan;30. Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan;31. International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;32. CREST, Japan Science and Technology Agency, Kawaguchi, Japan
Abstract:
><ol class=
  • Download : Download high-res image (185KB)
  • Download : Download full-size image
  • Keywords:SARS-CoV-2  COVID-19  Omicron  BA.2  BA.1  B.1.1.529  pathogenicity  fusogenicity  transmissibility
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号